Weight Loss & Metabolic Health
What Is Wegovy?
Last reviewed: May 2026 · Haute MD Editorial Team
Wegovy is the brand name for semaglutide approved by the FDA specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, and in adolescents 12 and older with obesity. It is the same molecule as Ozempic, manufactured by Novo Nordisk, but dosed up to 2.4 mg weekly and approved on-label for weight loss rather than diabetes.
How Wegovy differs from Ozempic
Both are semaglutide. The difference is dose, indication, and labeling. Ozempic is FDA-approved for type 2 diabetes at up to 2.0 mg weekly. Wegovy is FDA-approved for chronic weight management at up to 2.4 mg weekly. The mechanism, side-effect profile, and contraindications are identical. Insurance coverage differs significantly — Wegovy coverage for weight loss is improving but remains less consistent than Ozempic coverage for diabetes.
Expected results and clinical evidence
In the STEP-1 trial, adults without diabetes taking Wegovy lost an average of 14.9% of body weight over 68 weeks versus 2.4% with placebo, with improvements in waist circumference, blood pressure, lipids, and quality of life. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and pre-existing cardiovascular disease — leading to expanded FDA approval for cardiovascular risk reduction in 2024.
Dosing, side effects, and long-term use
Wegovy is titrated over 16+ weeks: 0.25 mg weekly for one month, then 0.5, 1.0, 1.7, and finally 2.4 mg maintenance. Slow titration reduces gastrointestinal side effects. Most common side effects are nausea, vomiting, diarrhea, constipation, and abdominal pain. Serious but rare risks include pancreatitis, gallbladder disease, and the thyroid C-cell tumor boxed warning. Obesity is a chronic disease, and most patients require ongoing therapy to maintain results — stopping typically leads to substantial weight regain within 1-2 years.
Frequently Asked Questions
How much weight will I lose on Wegovy?
Average weight loss in clinical trials was about 15% over 68 weeks, with one-third of patients losing 20% or more. Results depend on dose tolerance, lifestyle integration, and adherence.
Is Wegovy safe long-term?
Semaglutide has been studied for over a decade with a generally favorable safety profile. Long-term concerns include preserving lean mass (requires protein and resistance training), monitoring for pancreatitis or gallbladder disease, and the labeled thyroid contraindications.
What happens if I stop Wegovy?
In the STEP-4 extension trial, patients who stopped Wegovy regained approximately two-thirds of their lost weight within a year. Obesity medicine specialists generally treat GLP-1 therapy as long-term.
Can I take Wegovy with other weight loss medications?
Combining GLP-1s with other anti-obesity medications is sometimes done under specialist supervision, but is not standard. Most physicians optimize a single GLP-1 first before considering combinations.
Get Help Now
Speak with a Haute MD Internal Medicine physician
Dr. Alexander Golberg
Internal Medicine · New York, NY
View Profile
Dr. Kern Brar
MD
Internal Medicine · Oceanside, CA
View ProfileAre you a Internal Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · WEIGHT LOSS & METABOLIC HEALTH
What Is Ozempic?
Ozempic is the brand name for semaglutide, a once-weekly GLP-1 injection FDA-approved for type 2 diabetes. It's widely used off-label for weight loss; the on-label weight loss version is Wegovy.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
What Is Zepbound?
Zepbound is tirzepatide approved by the FDA for chronic weight management and obstructive sleep apnea. Same molecule as Mounjaro, with average weight loss of 20%+.
Read GuideGuide · WEIGHT LOSS & METABOLIC HEALTH
How Much Weight Can You Lose on GLP-1 Therapy?
Average weight loss is 15% on semaglutide (Wegovy) and 21% on tirzepatide (Zepbound) over 68-72 weeks. Top responders lose 25%+. Lifestyle integration significantly improves results.
Read Guide